General
Preferred name
ACETYLCARNITINE
Synonyms
Nicetile ()
levacecarnine hydrochloride ()
acetyl-L-carnitine ()
O-acetyl-L-carnitine ()
ALCAR ()
Acetylcarnitine hydrochloride, l- ()
Acetyl carnitine hcl ()
Zibren ()
Oristar acc ()
Oristar ach ()
Branigen ()
NSC-747431 ()
ST-200 ()
Normobren ()
Acetylcarnitine ()
P&D ID
PD073254
CAS
3040-38-8
Tags
available
drug
Drug indication
Discovery agent
Migraine
non-small cell lung carcinoma
Drug Status
approved
investigational
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION
Acetylcarnitine is not approved for any indication in the United states and Canada, but it is approved and indicated in Italy for cerebrovascular disorders, mental function disorders, peripheral nerve disorders, diabetic neuropathy, and nutritional supplementation; Portugal for mental function disorders; Argentina for cerebral vasculopathy, nutritional supplementation, and peripheral neuropathy; Chile for dementia; Philippines for cerebrovascular disorders and mental function disorders; Australia for nutritional supplementation; and India for nutritional supplementation to increase sperm count. Acetylcarnitine also has several potential therapeutic indications for which it is still being investigated: in Norway, acetylcarnitine is in a phase IV trial for prophylactic treatment of migraines; in Italy acetylcarnitine is in a phase II trial for use in patients with type 2 Diabetes Mellitus, a phase III trial for alleviating fatigue in patients with chronic hepatitis C, and for use in patients with Minimal Hepatic Encephalopathy; in the United States acetylcarnitine is in a phase II trial for the neurodegenerative disorder Progressive Supranuclear Palsy, a phase II and III trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy, a phase I and II trial for treating patients in septic shock, a phase II trial for bipolar depression, a phase II trial to reduce oxidative stress in patients with Sickle Cell disease, a phase I and II trial for chronic fatigue syndrome, and a study for preventing nerve damage in HIV patients; in China acetylcarnitine is in a phase III trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy; in the United Kingdom acetylcarnitine is being investigated for preventing nerve damage in HIV patients; and in Israel acetylcarnitine is being studied for the treatment of male infertility.; ; ;
DESCRIPTION
Acetyl-L-carnitine (O-Acetyl-L-carnitine) is a compound involved in human metabolic research. It has relevant applications in predicting metabolite biomarker changes using the Recon 2 metabolic reconstruction model and integrating and analyzing multiple data types, but its specific activity mechanism is not described in detail based on the existing information.
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
11
ChEMBL Drugs
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
36
Molecular Weight
203.12
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
0
Rotatable Bonds
5
Ring Count
0
Aromatic Ring Count
0
cLogP
-1.24
TPSA
66.43
Fraction CSP3
0.78
Chiral centers
1.0
Largest ring
0.0
QED
0.41
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Therapeutic Indication
Nootropic
Therapeutic Class
CNS & PNS
Pathway
Apoptosis
Metabolic Enzyme/Protease
Target
Caspase
Endogenous Metabolite
Source data
